FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025062866> ?p ?o ?g. }

• W2025062866 endingPage "234" @default.
• W2025062866 startingPage "228" @default.
• W2025062866 abstract "Background & Aim Interferon (IFN) negatively impacts patients’ well-being and patient-reported outcomes (PROs). Our aim was to assess PROs during treatment with an IFN-free regimen [sofosbuvir (SOF) + ribavirin (RBV)]. Methods Four PRO questionnaires [Short Form-36 (SF-36), Chronic Liver Disease Questionnaire-HCV (CLDQ-HCV), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Work Productivity and Activity Index: Specific Health Problem (WPAI:SHP)] were administered at baseline, end-of-treatment and post-treatment to 334 HCV genotype 2 and 3 patients (naïve or treatment-experienced) enrolled in the VALENCE study. Of these, 250 genotype 3 patients were treated for 24 weeks while 73 genotype 2 and 11 genotype 3 patients received 12 weeks of treatment. Results Baseline PRO scores were similar between the two arms of the study. Throughout and after treatment, patients receiving 12 or 24 weeks had similar FACIT-F, CLDQ-HCV, SF-36 and WPAI:SHP scores (all p >0.05). Compared to their own baseline scores, patients receiving SOF + RBV experienced modest declines in some aspects of SF-36, CLDQ-HCV, fatigue and WPAI:SHP scores (p = 0.04 to <0.0001). By follow-up week 12, all PRO scores returned to the pre-treatment levels (p >0.05). In patients achieving SVR-12 (regardless of the regimen), significant improvements were noted in general health (p = 0.0004), CLDQ-HCV (p <0.0001), fatigue (p = 0.005), emotional well-being (p <0.0001) and physical component summary score of SF-36 (p = 0.0022). In multivariate analysis, baseline depression, fatigue, insomnia, cirrhosis, and treatment-related adverse events were the most consistent predictors of PRO impairment (all p <0.05). Conclusions PROs are minimally impacted by SOF + RBV regimens. An additional 12 weeks of treatment does not substantially add to the PRO burden. Interferon (IFN) negatively impacts patients’ well-being and patient-reported outcomes (PROs). Our aim was to assess PROs during treatment with an IFN-free regimen [sofosbuvir (SOF) + ribavirin (RBV)]. Four PRO questionnaires [Short Form-36 (SF-36), Chronic Liver Disease Questionnaire-HCV (CLDQ-HCV), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Work Productivity and Activity Index: Specific Health Problem (WPAI:SHP)] were administered at baseline, end-of-treatment and post-treatment to 334 HCV genotype 2 and 3 patients (naïve or treatment-experienced) enrolled in the VALENCE study. Of these, 250 genotype 3 patients were treated for 24 weeks while 73 genotype 2 and 11 genotype 3 patients received 12 weeks of treatment. Baseline PRO scores were similar between the two arms of the study. Throughout and after treatment, patients receiving 12 or 24 weeks had similar FACIT-F, CLDQ-HCV, SF-36 and WPAI:SHP scores (all p >0.05). Compared to their own baseline scores, patients receiving SOF + RBV experienced modest declines in some aspects of SF-36, CLDQ-HCV, fatigue and WPAI:SHP scores (p = 0.04 to <0.0001). By follow-up week 12, all PRO scores returned to the pre-treatment levels (p >0.05). In patients achieving SVR-12 (regardless of the regimen), significant improvements were noted in general health (p = 0.0004), CLDQ-HCV (p <0.0001), fatigue (p = 0.005), emotional well-being (p <0.0001) and physical component summary score of SF-36 (p = 0.0022). In multivariate analysis, baseline depression, fatigue, insomnia, cirrhosis, and treatment-related adverse events were the most consistent predictors of PRO impairment (all p <0.05). PROs are minimally impacted by SOF + RBV regimens. An additional 12 weeks of treatment does not substantially add to the PRO burden." @default.
• W2025062866 created "2016-06-24" @default.
• W2025062866 creator A5013964835 @default.
• W2025062866 creator A5019627827 @default.
• W2025062866 creator A5026654277 @default.
• W2025062866 creator A5037741510 @default.
• W2025062866 creator A5045504446 @default.
• W2025062866 creator A5052742729 @default.
• W2025062866 creator A5057470139 @default.
• W2025062866 creator A5074202766 @default.
• W2025062866 creator A5080386622 @default.
• W2025062866 creator A5089037721 @default.
• W2025062866 date "2014-08-01" @default.
• W2025062866 modified "2023-10-01" @default.
• W2025062866 title "Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study" @default.
• W2025062866 cites W1965358723 @default.
• W2025062866 cites W2007668350 @default.
• W2025062866 cites W2019262762 @default.
• W2025062866 cites W2026673680 @default.
• W2025062866 cites W2035189635 @default.
• W2025062866 cites W2066274543 @default.
• W2025062866 cites W2072939862 @default.
• W2025062866 cites W2078251659 @default.
• W2025062866 cites W2080809577 @default.
• W2025062866 cites W2086325363 @default.
• W2025062866 cites W2086887894 @default.
• W2025062866 cites W2095348495 @default.
• W2025062866 cites W2104695445 @default.
• W2025062866 cites W2105258029 @default.
• W2025062866 cites W2113864802 @default.
• W2025062866 cites W2119156880 @default.
• W2025062866 cites W2120263188 @default.
• W2025062866 cites W2143468834 @default.
• W2025062866 cites W2154852580 @default.
• W2025062866 cites W2157961528 @default.
• W2025062866 doi "https://doi.org/10.1016/j.jhep.2014.04.003" @default.
• W2025062866 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24713186" @default.
• W2025062866 hasPublicationYear "2014" @default.
• W2025062866 type Work @default.
• W2025062866 sameAs 2025062866 @default.
• W2025062866 citedByCount "88" @default.
• W2025062866 countsByYear W20250628662014 @default.
• W2025062866 countsByYear W20250628662015 @default.
• W2025062866 countsByYear W20250628662016 @default.
• W2025062866 countsByYear W20250628662017 @default.
• W2025062866 countsByYear W20250628662018 @default.
• W2025062866 countsByYear W20250628662019 @default.
• W2025062866 countsByYear W20250628662020 @default.
• W2025062866 countsByYear W20250628662021 @default.
• W2025062866 countsByYear W20250628662022 @default.
• W2025062866 countsByYear W20250628662023 @default.
• W2025062866 crossrefType "journal-article" @default.
• W2025062866 hasAuthorship W2025062866A5013964835 @default.
• W2025062866 hasAuthorship W2025062866A5019627827 @default.
• W2025062866 hasAuthorship W2025062866A5026654277 @default.
• W2025062866 hasAuthorship W2025062866A5037741510 @default.
• W2025062866 hasAuthorship W2025062866A5045504446 @default.
• W2025062866 hasAuthorship W2025062866A5052742729 @default.
• W2025062866 hasAuthorship W2025062866A5057470139 @default.
• W2025062866 hasAuthorship W2025062866A5074202766 @default.
• W2025062866 hasAuthorship W2025062866A5080386622 @default.
• W2025062866 hasAuthorship W2025062866A5089037721 @default.
• W2025062866 hasConcept C126322002 @default.
• W2025062866 hasConcept C1862650 @default.
• W2025062866 hasConcept C203014093 @default.
• W2025062866 hasConcept C2522874641 @default.
• W2025062866 hasConcept C2775999097 @default.
• W2025062866 hasConcept C2776455275 @default.
• W2025062866 hasConcept C2778390639 @default.
• W2025062866 hasConcept C2780040827 @default.
• W2025062866 hasConcept C2781413609 @default.
• W2025062866 hasConcept C3020491458 @default.
• W2025062866 hasConcept C71924100 @default.
• W2025062866 hasConcept C90924648 @default.
• W2025062866 hasConceptScore W2025062866C126322002 @default.
• W2025062866 hasConceptScore W2025062866C1862650 @default.
• W2025062866 hasConceptScore W2025062866C203014093 @default.
• W2025062866 hasConceptScore W2025062866C2522874641 @default.
• W2025062866 hasConceptScore W2025062866C2775999097 @default.
• W2025062866 hasConceptScore W2025062866C2776455275 @default.
• W2025062866 hasConceptScore W2025062866C2778390639 @default.
• W2025062866 hasConceptScore W2025062866C2780040827 @default.
• W2025062866 hasConceptScore W2025062866C2781413609 @default.
• W2025062866 hasConceptScore W2025062866C3020491458 @default.
• W2025062866 hasConceptScore W2025062866C71924100 @default.
• W2025062866 hasConceptScore W2025062866C90924648 @default.
• W2025062866 hasIssue "2" @default.
• W2025062866 hasLocation W20250628661 @default.
• W2025062866 hasLocation W20250628662 @default.
• W2025062866 hasOpenAccess W2025062866 @default.
• W2025062866 hasPrimaryLocation W20250628661 @default.
• W2025062866 hasRelatedWork W1732930179 @default.
• W2025062866 hasRelatedWork W2336355105 @default.
• W2025062866 hasRelatedWork W2341282998 @default.
• W2025062866 hasRelatedWork W2520265236 @default.
• W2025062866 hasRelatedWork W2521436743 @default.
• W2025062866 hasRelatedWork W2585250246 @default.
• W2025062866 hasRelatedWork W2612654848 @default.

• next